2025
Interleukin-6 Trans Signaling Regulates Neutrophilic Inflammation in Alcohol-Associated Hepatitis
Sarode G, Hsu M, Haj F, Barace S, Argemi J, Liu M, Pandita P, Cao S, Shah V, Gui D, Bataller R, Rachakonda V. Interleukin-6 Trans Signaling Regulates Neutrophilic Inflammation in Alcohol-Associated Hepatitis. American Journal Of Pathology 2025 PMID: 40562277, DOI: 10.1016/j.ajpath.2025.05.023.Peer-Reviewed Original ResearchSTAT3-dependent gene expressionAlcohol-associated hepatitisSTAT3 activationIL-6 trans signalingRNA-seqTrans signalingIL-6R expressionGene expressionLiver RNA-seqIL-6Hyper-IL-6Neutrophilic inflammationIL-6 receptorIL-6RTGF-b1Intrahepatic neutrophil infiltrationLiver injury responsePathophysiology of AHTranscript enrichmentNegative regulatorChronic liver failureLiver disease patientsMembrane-boundSTAT3Severe AHTargeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease
Yang Y, Duan Y, Lang S, Fondevila M, Schöler D, Harberts A, Cabré N, Chen S, Shao Y, Vervier K, Miyamoto Y, Zhang X, Chu H, Yang L, Tan C, Eckmann L, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Stärkel P, Lawley T, Schnabl B. Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease. Cell Host & Microbe 2025, 33: 957-972.e6. PMID: 40441146, PMCID: PMC12162233, DOI: 10.1016/j.chom.2025.05.003.Peer-Reviewed Original ResearchConceptsEthanol-induced liver diseaseAlcohol-associated liver diseaseAlcohol-associated hepatitisLiver diseaseGenome of Escherichia coliE. coliMetagenomic sequencing of fecal samplesInternational cohort of patientsGenetic manipulation of bacteriaGnotobiotic mouse modelOutcomes of patientsManipulation of bacteriaCohort of patientsScavenger receptor MARCOGlobal health burdenVirulence factorsMetagenomic sequencingGut microbiotaGenetic manipulationDisease progressionMouse modelKupffer cellsKpsMBacterial spreadInternational cohortModerate alcohol-associated hepatitis: A real-world multicenter study
Idalsoaga F, Díaz L, Dunn W, Mehta H, Muñoz K, Caldentey V, Arnold J, Ayares G, Mortuza R, Sarin S, Maiwall R, Zhang W, Qian S, Simonetto D, Singal A, Elfeki M, Ramirez-Cadiz C, Malhi G, Ahmed A, Homsi H, Abid Z, Cabezas J, Echavarría V, Poca M, Soriano G, Cuyas B, Cots M, La Tijera M, Ayala-Valverde M, Perez D, Gomez J, Abraldes J, Al-Karaghouli M, Jalal P, Ibrahim M, García-Tsao G, Goyes D, Skladaný L, Havaj D, Sulejova K, Selcanova S, Rincón D, Chacko K, Restrepo J, Yaquich P, Toro L, Shah V, Arrese M, Kamath P, Bataller R, Arab J. Moderate alcohol-associated hepatitis: A real-world multicenter study. Hepatology Communications 2025, 9: e0673. PMID: 40131003, PMCID: PMC11936654, DOI: 10.1097/hc9.0000000000000673.Peer-Reviewed Original ResearchConceptsSevere alcohol-associated hepatitisNeutrophil-to-lymphocyte ratioMaddrey's discriminant functionModerate AHMultiple organ failureOrgan failureMulticenter retrospective cohort studyAlcohol-associated hepatitisCumulative survival rateRetrospective cohort studyReceiver operating characteristic curveLong-term outcomesShort-term mortalityMortality scoring systemsPrognostic factorsSerum bilirubinMELD scoreWell-characterized diseaseClinical profileMedian MELDCohort studyCox regressionMultivariate analysisTherapeutic strategiesSurvival rate
2024
US mortality trends from alcohol‐associated hepatitis by sex, age, race, and ethnicity, 1999–2020
Banini B, Chauhan S, Amatya A, Dashti F, Zahrawi K, Zahrawi F, Mehal W, McKee S. US mortality trends from alcohol‐associated hepatitis by sex, age, race, and ethnicity, 1999–2020. Alcohol Clinical And Experimental Research 2024, 49: 358-367. PMID: 39739407, DOI: 10.1111/acer.15515.Peer-Reviewed Original ResearchAmerican Indians/Alaska NativesMortality rate ratiosIndians/Alaska NativesCenters for Disease Control and Prevention Wide-ranging Online DataUS Centers for Disease Control and Prevention Wide-ranging ONline DataWide-ranging Online DataMortality rateUS mortality trendsAlcohol-associated hepatitisJoinpoint regression analysisYoung adultsCross-sectional studyAlcohol-associated liver diseaseYoung adult femalesHigh-risk populationOnline dataMortality trendsSteepest increaseUnited StatesYear compared to baselineCalendar trendsSociodemographic factorsRacial/ethnic groupsEpidemiological researchRate ratiosComparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis
Islam A, Díaz L, Idalsoaga F, Guizzetti L, Mortuza R, Dunn W, Singal A, Simonetto D, Ramirez-Cadiz C, Zhang W, Qian S, Cabezas J, Sarin S, Maiwall R, Jalal P, La Tijera F, Skladany L, Bystrianska N, Rincon D, Chacko K, Cots M, Garcia-Tsao G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis. Hepatology Communications 2024, 8: e0573. PMID: 39445912, PMCID: PMC11512629, DOI: 10.1097/hc9.0000000000000573.Peer-Reviewed Original ResearchS2091 Outcomes of Alcohol-Associated Hepatitis in Hospitalized Patients With Prior Bariatric Surgery: A Nationwide Analysis, 2016-2020
Boateng S, Ameyaw P, Mathialagan K, Boateng W, Njei B. S2091 Outcomes of Alcohol-Associated Hepatitis in Hospitalized Patients With Prior Bariatric Surgery: A Nationwide Analysis, 2016-2020. The American Journal Of Gastroenterology 2024, 119: s1493-s1495. DOI: 10.14309/01.ajg.0001037732.36409.47.Peer-Reviewed Original ResearchViral antibody response predicts morbidity and mortality in alcohol-associated hepatitis
Hsu C, Wang L, Maestri E, Jacob A, L. W, Mayo S, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Investigators A, Wang X, Schnabl B. Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis. Hepatology 2024, 82: 127-139. PMID: 39325984, PMCID: PMC11932942, DOI: 10.1097/hep.0000000000001046.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderHigher Child-Pugh scoreSerological profileAntibody responseAssociated with very high mortalityUse disorderDecompensation of liver diseaseChild-Pugh scoreActive alcohol useNinety-day mortalityAssociated with decompensationMulticenter observational studyViral antibody responseMonths of diagnosisAntibody repertoireSera of patientsMultiorgan dysfunctionPoor prognosisNinety-daySerological biomarkersHealthy controlsPatient seraLiver diseaseAntibody targetingRelationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
Al-Karaghouli M, Ventura-Cots M, Wong Y, Genesca J, Bosques F, Brown R, Mathurin P, Louvet A, Shawcross D, Vargas V, Verna E, Schnabl B, Caballeria J, Shah V, Kamath P, Lucey M, Garcia-Tsao G, Bataller R, Abraldes J. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design. Hepatology Communications 2024, 8: e0495. PMID: 39082963, DOI: 10.1097/hc9.0000000000000495.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisTrial designRandomized Controlled TrialsShort-term mortalityInclusion criteriaPredictive valuePrognostic valueControlled TrialsShort-term benefitsEfficient trial designTrial outcomesAssociated with significant mortalityCourse of AHCohort of patientsTreatment decisionsSample sizeOrdinal outcomesMortalityOrdinal scaleMELD valuesLandmark analysisTransplant allocationTrialsOutcomesTransplantationFaecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis
Kreimeyer H, Gonzalez C, Fondevila M, Hsu C, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez D, Schnabl B. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis. Gut 2024, 74: 103-115. PMID: 39033024, PMCID: PMC11631684, DOI: 10.1136/gutjnl-2024-332730.Peer-Reviewed Original ResearchAlcohol-associated hepatitisShort-term survivalMulticentre cohortSeverity of ALDAlcohol-associated liver diseaseIndependent validation cohortInduce gut dysbiosisNon-invasive markerAlcohol-use disordersNeutrophil degranulationPrediction of short-term survivalPrognostic effectHepatic neutrophilsValidation cohortBacterial translocationNeutrophil granulesMPO levelsLiver diseaseFecal biomarkersTandem mass tagPatientsGut dysbiosisLiver damageDisease severityNeutrophilsOutcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
T. A, Allegretti A, Cullaro G, Ouyang T, Asrani S, Chung R, Przybyszewski E, Wilechansky R, Robinson J, Sharma P, Simonetto D, Jalal P, Orman E, Wadei H, St. Hillien S, Saly D, Ufere N, Dageforde L, Regner K, Belcher J, Patidar K, Consortium F. Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium. Alimentary Pharmacology & Therapeutics 2024, 60: 778-786. PMID: 39010302, PMCID: PMC11349455, DOI: 10.1111/apt.18159.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAcute kidney injuryAcute kidney injury phenotypesHepatorenal syndromeMELD-NaDevelopment of acute kidney injuryCumulative incidence of deathConsecutive adult patientsOutcomes of patientsAlcohol Abuse and Alcoholism (NIAAANon-AH groupRenal replacement therapyPresence of AHAcute tubular necrosisRetrospective cohort studyPredictors of mortalityIncidence of deathAKI stageClinical courseReplacement therapyAdult patientsKidney injuryCumulative incidencePoor prognosisTubular necrosisNeutrophils insert elastase into hepatocytes to regulate calcium signaling in alcohol-associated hepatitis
Ogino N, Leite M, Guerra M, Kruglov E, Asashima H, Hafler D, Ito T, Pereira J, Peiffer B, Sun Z, Ehrlich B, Nathanson M. Neutrophils insert elastase into hepatocytes to regulate calcium signaling in alcohol-associated hepatitis. Journal Of Clinical Investigation 2024, 134: e171691. PMID: 38916955, PMCID: PMC11324315, DOI: 10.1172/jci171691.Peer-Reviewed Original ResearchAlcohol-associated hepatitisReduced cell proliferationCalcium channel expressionCalcium signaling mechanismsIntracellular calcium channelsCell proliferationRegulate calcium signalingNeutrophil extracellular trapsChannel expressionNeutrophil granule proteinsCalcium channelsNeutrophil infiltrationPatient specimensGranule proteasesMouse modelHealthy subjectsLiver diseaseExtracellular trapsCalcium signalingSerpin E2NeutrophilsElastase activityHepatitisTissue remodelingSignaling mechanismsAn artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn W, Li Y, Singal A, Simonetto D, Díaz L, Idalsoaga F, Ayares G, Arnold J, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez-Cadiz C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Dunn N, Waleed M, Stefanescu H, Bumbu A, Horhat A, Attar B, Agrawal R, Cabezas J, Echavaría V, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Guerra-Salazar P, Skladaný L, Kubánek N, Prado V, Clemente-Sanchez A, Rincon D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Hudson D, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. Hepatology 2024, 80: 1196-1211. PMID: 38607809, PMCID: PMC11798100, DOI: 10.1097/hep.0000000000000883.Peer-Reviewed Original ResearchAlcohol-associated hepatitisValidation cohortArtificial intelligenceModified Glasgow scoreMaddrey's discriminant functionMortality rateGlobal cohort studyShort-term mortalityPost-test probabilityApproximate mortality ratesSteroid therapyGlasgow scoreAH patientsSteroid useTransplant indicationRetrospective studyDerivation cohortLaboratory valuesCohort studyClinical trialsGlobal cohortPrognostic modelScoring systemAI algorithmsCohortComplement protein signatures in patients with alcohol-associated hepatitis
Taiwo M, Huang E, Pathak V, Bellar A, Welch N, Dasarathy J, Streem D, McClain C, Mitchell M, Barton B, Szabo G, Dasarathy S, Consortium A, Schaefer E, Luther J, Day L, Ouyang X, Suyavaran A, Mehal W, Jacobs J, Goodman R, Rotroff D, Nagy L. Complement protein signatures in patients with alcohol-associated hepatitis. JCI Insight 2024, 9: e174127. PMID: 38573776, PMCID: PMC11141929, DOI: 10.1172/jci.insight.174127.Peer-Reviewed Original ResearchAlcohol-associated hepatitisSevere AHAlcohol use disorderAlcoholic cirrhosisHealthy controlsPredicting 90-day mortalityComplement proteinsSerum proteome of patientsEthanol-induced liver injurySerum proteomeDevelopment of effective therapiesProteome of patientsAssociated with pro-inflammatory cytokinesProtein signaturesPro-inflammatory cytokinesCoagulation factors IINon-invasive biomarkersDiagnostic challengeSerine protease 1Murine modelEffective therapyLiver injuryPrognostic biomarkerHepatic inflammationC1q binding proteinSerum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis
Yamazaki T, Kouno T, Hsu C, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Schnabl B. Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis. Hepatology 2024, 80: 403-417. PMID: 38377466, PMCID: PMC11268475, DOI: 10.1097/hep.0000000000000777.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderSevere AHAH patientsAhR activationMicrobiota-derived tryptophan metabolitesSurvival rateAssociated with high mortalityCumulative survival rateAssociated with survivalAryl hydrocarbon receptor activationMulticenter cohortFecal metabolomePrognostic markerTryptophan metabolitesReceptor activationAryl hydrocarbon receptorPatientsUse disorderAH cohortSerumHigher mortalityAhRHepatitisCohortP-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY
Idalsoaga F, Díaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY. Annals Of Hepatology 2024, 29: 101206. DOI: 10.1016/j.aohep.2023.101206.Peer-Reviewed Original ResearchRenal replacement therapyVariables associated with mortalityModerate AHAlcohol-associated hepatitisPrognostic factorsLiver transplantationMaddrey's discriminant functionAssociated with high mortalityMultiple organ failureRetrospective cohort studyMultivariate-adjusted modelsShort-term mortalityAssociated with mortalityCompeting-risks modelMedian ageCause of deathReplacement therapyMulticenter studyMELD scoreOrgan failureUnivariate analysisCohort studyFrequent causeSevere entitySurvival rateP- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY
Idalsoaga F, Diaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Agrawal B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY. Annals Of Hepatology 2024, 29: 101227. DOI: 10.1016/j.aohep.2023.101227.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAcute kidney injurySevere AHPentoxifylline useLiver transplantationKidney injuryMaddrey's discriminant functionAssociated with increased mortalityHistory of cirrhosisSubgroup of patientsRetrospective cohort studyMultivariate-adjusted modelsEffect of pentoxifyllineAssociated with mortalityCompeting-risks modelMedian ageSerum creatinineMELD scoreUnivariate analysisCohort studyFemale sexPentoxifyllineDecreased survivalSevere entityPatientsEmergency services utilization by patients with alcohol‐associated hepatitis: An analysis of national trends
Sengupta S, Anand A, Lopez R, Weleff J, Wang P, Bellar A, Attaway A, Welch N, Dasarathy S. Emergency services utilization by patients with alcohol‐associated hepatitis: An analysis of national trends. Alcohol Clinical And Experimental Research 2024, 48: 98-109. PMID: 38193831, PMCID: PMC10783841, DOI: 10.1111/acer.15223.Peer-Reviewed Original ResearchAlcohol-associated hepatitisNationwide Emergency Department SampleEmergency departmentRate of ED visitsED visitsLiver diseaseProportion of young patientsComplications of liver diseaseSeverity of diseaseED utilizationAH diagnosisPrimary AHPatients seeking careOutcome of ED visitsYounger patientsHighest rate of ED visitsEmergency Department SampleSevere formHospitalized patientsTemporal trendsPatientsEmergency service utilizationED utilization ratesRate of visitsLogistic regression
2023
Adding Inflammatory Markers and Refining National Institute on Alcohol Abuse and Alcoholism Criteria Improve Diagnostic Accuracy for Alcohol-associated Hepatitis
Avitabile E, Díaz A, Montironi C, Pérez-Guasch M, Gratacós-Ginès J, Hernández-Évole H, Moreira R, Sehrawat T, Malhi H, Olivas P, Hernández-Gea V, Bataller R, Shah V, Kamath P, Ginès P, Pose E. Adding Inflammatory Markers and Refining National Institute on Alcohol Abuse and Alcoholism Criteria Improve Diagnostic Accuracy for Alcohol-associated Hepatitis. Clinical Gastroenterology And Hepatology 2023, 21: 3080-3088.e9. PMID: 37004974, DOI: 10.1016/j.cgh.2023.03.023.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisAlcohol-related liver diseaseAlcoholic steatohepatitisLiver biopsyDiagnostic accuracyLiver diseaseValidation cohortNIAAA criteriaAlcohol abuseSevere alcohol-associated hepatitisC-reactive proteinGold standardNational InstituteInflammatory markersConsecutive patientsDerivation cohortHistological diagnosisMayo ClinicHospital ClínicTherapeutic studiesAlcoholism criteriaClinical investigatorsConsensus criteriaAbstractTextNoninvasive diagnosisMELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis
Díaz L, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Valverde M, Perez D, Gómez J, Escarate R, Villalón A, Ramírez C, Hernandez-Tejero M, Zhang W, Qian S, Simonetto D, Ahn J, Buryska S, Dunn W, Mehta H, Agrawal R, Cabezas J, García-Carrera I, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Abdulsada S, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Salazar P, Skladaný L, Bystrianska N, Clemente-Sanchez A, Villaseca-Gómez C, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Castro-Sanchez S, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Louvet A, García-Tsao G, Roblero J, Abraldes J, Shah V, Kamath P, Arrese M, Singal A, Bataller R, Arab J. MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis. JHEP Reports 2023, 5: 100727. PMID: 37456675, PMCID: PMC10339256, DOI: 10.1016/j.jhepr.2023.100727.Peer-Reviewed Original ResearchRenal replacement therapy requirementAlcohol-associated hepatitisMaddrey's discriminant functionShort-term mortalityFurther prospective studiesMELD-NaTherapy requirementsProspective studyEnd-stage liver diseaseHigh short-term mortalityGlobal cohortRetrospective cohort studyCompeting-risk analysisTime-dependent AUCMELD-sodiumLiver transplantationMalnourished patientsCohort studyEstablishment of treatmentLiver diseaseABIC scoreLargest global cohortMAIN OUTCOMEMortality predictionDeLong method
2021
The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study
Morales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes J, Cruz-Lemini M, Thursz M, Atkinson S, Sarin S, Kim W, Chavez-Araujo R, la Tijera M, Singal A, Shah V, Kamath P, Duarte-Rojo A, Charles E, Vargas V, Jager M, Rautou P, Rincon D, Zamarripa F, Restrepo-Gutiérrez J, Torre A, Lucey M, Arab J, Mathurin P, Louvet A, García-Tsao G, González J, Verna E, Brown R, Argemi J, Fernández-Carrillo C, Clemente A, Alvarado-Tapias E, Forrest E, Allison M, Bataller R. The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study. The American Journal Of Gastroenterology 2021, 117: 301-310. PMID: 34962498, PMCID: PMC8999152, DOI: 10.14309/ajg.0000000000001596.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisMaddrey's discriminant functionShort-term mortalityMELD scoreMELD-sodiumEnd-stage liver disease (MELD) scoreGlasgow alcoholic hepatitis scoreMaddrey Discriminant Function scoreAlcohol‐Associated HepatitisMedian MELD scoreLiver Disease scoreInternational normalized ratioCharacteristic curveMDF scoreCause mortalityPrimary outcomeTertiary centerLaboratory variablesCreatinine scoreNormalized ratioFunction scoresDisease scoreMortality predictionMortalityOutcome prediction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply